A detailed history of Slocum, Gordon & CO LLP transactions in Abbott Laboratories stock. As of the latest transaction made, Slocum, Gordon & CO LLP holds 4,250 shares of ABT stock, worth $442,085. This represents 0.37% of its overall portfolio holdings.

Number of Shares
4,250
Previous 4,700 9.57%
Holding current value
$442,085
Previous $517,000 6.58%
% of portfolio
0.37%
Previous 0.46%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$109.52 - $120.96 $49,284 - $54,432
-450 Reduced 9.57%
4,250 $483,000
Q4 2023

Feb 14, 2024

BUY
$90.19 - $110.4 $423,893 - $518,880
4,700 New
4,700 $517,000
Q2 2023

Oct 23, 2023

BUY
$100.78 - $112.29 $473,666 - $527,763
4,700 New
4,700 $512,000
Q1 2023

Dec 14, 2023

BUY
$96.86 - $114.01 $455,242 - $535,847
4,700 New
4,700 $475,000
Q4 2022

Dec 06, 2023

BUY
$95.06 - $111.52 $446,877 - $524,255
4,701 New
4,701 $516 Million

Others Institutions Holding ABT

About ABBOTT LABORATORIES


  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $182B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track This Portfolio

Track Slocum, Gordon & CO LLP Portfolio

Follow Slocum, Gordon & CO LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Slocum, Gordon & CO LLP, based on Form 13F filings with the SEC.

News

Stay updated on Slocum, Gordon & CO LLP with notifications on news.